Clinical Trials Browser

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

NCT03153462 2023-11-08

ZUMA-9

Approved for marketing

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04162756 2021-10-14

ZUMA-18

Approved for marketing

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT01632826 2019-11-12

PEXIUS

Approved for marketing

Plasma cell

Multiple Myeloma, Recurrence

NCT02437019 2017-03-20

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Approved for marketing

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Vorasidenib Expanded Access Program

ZUMA-9

ZUMA-18

PEXIUS

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)